ClinicalTrials.gg
Not yet recruitingNCT07531303Updated Apr 15, 2026

VenusP-Valve™ System Long-term Follow-up 6-10 Years

An observational study in Native Right Ventricle Outflow Tract(RVOT) Dysfunction, sponsored by Venus MedTech (HangZhou) Inc.. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Venus MedTech (HangZhou) Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
55
Sex
All
01

Study summary

The goal of this study is to assess the long-term safety, efficacy and performance of VenusP-Valve™ implantation. in all subjects who provided informed consent and received VenusP-Valve™ implantation in the VenusP-Valve™ system CE registration study (Protocol ID Number: VMT-001CE; NCT02846753).

Annual clinic visits will be conducted from year 6 through year 10 post-implantation, including transthoracic echocardiography, New York Heart Association (NYHA) functional classification assessment, adverse event evaluation, and review of cardiovascular medication use at each visit..

02

Conditions studied

  • Native Right Ventricle Outflow Tract(RVOT) Dysfunction
03

In context

Lead sponsor

Venus MedTech (HangZhou) Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All subjects who provided informed consent and received VenusP-Valve™ implantation in the VenusP-Valve™ system CE registration study (Protocol ID Number: VMT-001CE; NCT02846753).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written as approved by the ethics committee and regulatory authority if applicable of the respective clinical site

Exclusion criteria

Exclusion Criteria:

  • The investigators consider that the patients are not suitable to participate in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
55 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Right ventricular reverse remodeling and improvement rate of right ventricular function were followed up at 6 months after operation

    The right ventricular reverse remodeling and the improvement rate of right ventricular function at 6 months after operation were defined as the 6-month follow-up The right ventricular end-diastolic volume index measured by CMR was within the normal range, that is, RVEDVI≤108mL/m2.

    Time frame: From enrollment to month-6 post procedure.

Secondary outcomes

  1. adverse events and moderate or greater pulmonary regurgitation at 6 years, 7 years, 8 years, 9 years and 10 years.

    1. Occurrence of the following adverse events at 6 years, 7 years, 8 years, 9 years and 10 years: * Device migration/embolization * Valvar thrombosis * Thromboembolism * Bleeding * Paravalvular leak * Endocarditis * Nonstructural dysfunction * Explant * Hemolysis * Arrhythmias 2. Moderate or greater pulmonary regurgitation by echocardiography at 6 years, 7 years, 8 years, 9 years and 10 years.

    Time frame: From enrollment to 10 years post procedure.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2029, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
Apr 15, 2026
StartEst.
May 2026
Primary completionEst.
Dec 2029
CompletionEst.
Jun 2030
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07531303
Lead sponsor
Venus MedTech (HangZhou) Inc.
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
May 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Apr 15, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion